No Data
Deqi Pharmaceutical-B (06996.HK): The indication for the use of Tislelizumab in the treatment of diffuse large B-cell lymphoma has been successfully included in the 2024 edition of the National Medical Insurance pharmaceutical directory.
On November 28, Gelonghui reported that德琪医药-B (06996.HK) announced that the new indication for希维奥 (Selinexor tablets) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two lines of systemic treatment has been included in the National Healthcare Security Administration's medication catalog (NRDL) for 2024, which will take effect on January 1, 2025.
Express News | Antengene Corp - Xpovio's Indication in Dlbcl Included in 2024 China National Reimbursement Drug List
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
No Data
No Data